Actively Recruiting

Age: 18Years - 85Years
All Genders
ID06736847

Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery Following D2 Lymphadenectomy Plus Complete Mesogastric Excision in Patients Who Received Distal Gastrectomy: A Prospective Observational Study

Led by Jichao Qin · Updated on 2025-09-02

200

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating lymph node spread and tumor deposits in the posterior gastric mesentery after distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in patients with gastric cancer. This study aims to provide evidence to improve surgical standards by examining how thoroughly lymph nodes are cleared using this approach compared to traditional methods. The study focuses on patients with advanced or certain early-stage gastric cancers who undergo this specific surgical procedure. Participants receive distal gastrectomy combined with D2 lymphadenectomy and CME, which involves removal of five major mesenteries including the posterior gastric mesentery. This procedure is studied because it removes more lymph nodes than traditional D2 lymphadenectomy alone and may reduce cancer recurrence. The study observes patients who have already undergone this surgery to assess lymph node involvement and tumor deposits. During the study, researchers monitor the rate of lymph node metastasis and tumor deposits in the posterior gastric mesentery for about one year after surgery. Patients are evaluated through pathological examination of surgical specimens and clinical follow-up. The study collects data to help standardize surgical methods for gastric cancer and improve long-term outcomes. Participation lasts on average one year, focusing on careful pathological and clinical assessment after the surgical treatment.

CONDITIONS

Brief Title

Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged older than 18 years and younger than 85 years
  • Primary gastric adenocarcinoma confirmed by preoperative pathology
  • cT2-4N0-3M0 stage based on preoperative evaluation using AJCC Cancer Staging Manual 7th Edition
  • Patients who received distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
  • American Society of Anesthesiologists (ASA) class I, II, or III
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Negative preoperative biopsy
  • Tumor too advanced or with metastasis (cT4b or M1)
  • Body mass index over 30 kg/m2
  • Underwent total or proximal gastrectomy
  • Received neoadjuvant chemotherapy or radiotherapy before surgery
  • Previous upper abdominal surgery
  • Having other malignant diseases
  • Refusal of surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for preoperative evaluation and consent

Surgery and Immediate Post-operative Care

Duration - Surgery day plus immediate recovery period

Participants undergo distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) for gastric cancer followed by immediate post-operative care.

1 surgery visit and hospital stay for recovery

Post-operative Follow-up

Duration - Approximately 1 year

Participants are followed for about 1 year after surgery to monitor lymph node metastasis and tumor deposit in the posterior gastric mesentery.

Multiple follow-up visits over 1 year

Trial Site Locations

Total: 1 location

1

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310000

Actively Recruiting

Loading map...

Research Team

T

Tao Wang, Ph.d

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase III Randomized Study of Disitamab Vedotin, Trastuzum...

Gastric Carcinoma

Actively Recruiting

1 location

Dose Escalation Trial of BI 765049 in Advanced, Unresectable...

Colorectal Carcinoma

Actively Recruiting

3 locations

Tumor Deposit at the Fusion Site of the Right Gastric Mesent...

Gastric Carcinoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here